Navigation Links
Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
Date:7/25/2012

potential to impact both metastatic and primary tumors. In our previously reported randomized Phase 2 dose-ranging study in HCC with intratumoral delivery, we showed a statistically significant benefit in overall survival in the high dose group, which we believe was due, in large part, to the systemic delivery of JX-594 at that dose level."

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic immunotherapy designed to selectively target and destroy cancer cells through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or intravenously, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 130 treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. JX-594 has had a favorable safety profile to date with predictable and generally mild side effects that typically include flu-like symptoms that resolve in 24 to 48 hours.

JX-594 is the most advanced product candidate from Jennerex's proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform.  SOLVE takes advantage of the natural attributes of poxviruses as well as their potential to be engineered to produce oncolytic immunotherapies that can target and destroy solid tumors both systemically and locally.  The vaccinia poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic abnormalities in cancer cells. JX-594 was engin
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Annual Meeting that they have joined forces to ... collaboration is the first of its kind and ... outcomes. NICO,s BrainPath® interventional access technology and Synaptive,s ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics ... system: the ability to collect human data at 30X depth, ... single chip.  This new capability was established and demonstrated for ... Irys TM System and will be rolled ... months. BioNano will be showcasing this advancement at the ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... WASHINGTON, Nov. 16, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... for employers, unions, and state employee plans, according to ... Pharmaceutical Care Management Association (PCMA).  The use of ...
... Nov. 16, 2011   The proliferation of brand drug ... to more expensive brands, will increase costs by $308 ... unions, and state employee plans, according to new research ... Management Association (PCMA).  The use of these promotions ...
Cached Medicine Technology:Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $1 Billion in New Jersey 2Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $308 Million in Arkansas 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period ... for Research (AIR) finds that three out of four Americans ... 42 percent say they are not likely or only somewhat ... coverage. , The AIR survey found wide gaps in Americans’ ... correctly how much they owe for a routine doctor’s visit. ...
(Date:10/22/2014)... October 22, 2014 Best Cheap Hosting ... the world. The site has recently announced that iPower ... supplier for people from around the world. , “iPower ... operation today and is providing various kinds of useful ... company insists on offering excellent customer service and a ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a ... the face, it certainly can be difficult to choose the ... extra favor by doing it the healthy way? Set aside ... to your body, exercise regularly, and choose foods with the ... weight; you need to exercise more and eat less. Despite ...
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... out, typical seasonal flu, experts say, , THURSDAY, Dec. 24 ... start of the seasonal flu season. , But since the ... has been typical about influenza, one of the most common ... flu research right now, some experts are speculating that seasonal ...
... , FOUNTAIN VALLEY, Calif., Dec. 24 Today ... considering selling its stake in Zealous Interactive in order to ... CFO Gary R. Gottlieb said, "We are in detailed talks ... web, media and marketing assets owned by Zealous Interactive, a ...
... ... drug information on Android devices, , ... Hudson, OH (PRWEB) December 24, 2009 -- Lexi-Comp, ... has released an application for Google Android devices. This latest platform expands ...
... ... Lebhar-Friedman, Inc. announces the sale of Dowden Professional Publications, the Dowden medical journals ... Management, Current Psychiatry, Journal of Family Practice and Mayo Clinical Proceedings. , ... (PRWEB) December ...
... ... Haydon Kerk Motion Solutions, Inc., a leading manufacturer of linear motion products, introduces the ... performance. , ... Waterbury, CT (PRWEB) December 24, 2009 -- Haydon Kerk Motion Solutions, Inc ., ...
... , Children,s National Posts Favorite Story on ... Obama read the holiday classic ,Twas the Night before Christmas ... National Medical Center. A video of the classic story being ... Children,s National website, so children and families around the country and ...
Cached Medicine News:Health News:Swine Flu May Be Rewriting the Flu-Season Script 2Health News:Swine Flu May Be Rewriting the Flu-Season Script 3Health News:Zealous in Talks to Sell Its Interactive Subsidiary; Company Said to be Considering All Options. 2Health News:Lexi-Comp Now Available for Android™ 2Health News:DeSilva+Phillips, Mediabankers Client Lebhar-Friedman, Inc. Announces the Sale of Dowden Professional Publications to Quadrant HealthCom Inc. 2Health News:Haydon Kerk Motion Solutions Introduces the NEW G4 37000 Series Stepper Motor Linear Actuator 2Health News:'Twas the Night Before Christmas: First Lady Michelle Obama Reads the Holiday Classic 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: